Abstract
Accumulating evidence demonstrates that growing adipose tissues produce various proangiogenic factors, cytokines and adipokines, which induce neovascularization. Similar to malignant tissue growth, expansion of fat mass would not be achieved without switching on an angiogenic phenotype. Several recent studies using mouse genetic and high caloric diet-fed obese models validate this concept of preventing obesity by delivery of angiogenesis inhibitors. It is predicted, although it needs to be further proved, that antiangiogenic agents might be used either alone or in combinations with other existing therapeutic agents for the treatment of obesity. This review article focuses on discussing molecular mechanisms of angiogenesis in adipose tissues, defining vascular therapeutic targets, and employing antiangiogenic agents for prevention and treatment of obesity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
